title: Does buprenorphine maintenance improve the quality of life of opioid users?
abstract: OBJECTIVE
  The quality of life (QOL) of substance abusers is known to be severely impaired. Information on impact of opioid maintenance treatment on the QOL of opioid dependent subjects though available from the developed countries, is lacking from India. This study was carried out to assess the impact of buprenorphine maintenance treatment on the quality of life (QOL) of opioid dependent subjects at nine months follow up.
  
  
  METHODS
  Based on specified inclusion criteria a total of 231 subjects were recruited from five participating centres across India. They received sublingual buprenorphine as a directly observed therapy along with brief psychosocial intervention (provided in groups of 8-10 subjects) after intake in to the study. The WHOQOL-BREF scale domain scores obtained at baseline were compared to domain scores at nine months follow up.
  
  
  RESULTS
  At nine months follow up, among the 64.1 per cent retained in buprenorphine maintenance, there was a significant (P<0.001) decline in opioid use from 24.9 ± 10.1 days at baseline to 1.7 ± 4.7 days at nine months follow up and improvements in score of the four WHOQOL-BREF domains (Physical, Psychological, Social relationships and Environment).
  
  
  CONCLUSIONS
  The results showed the beneficial effects of buprenorphine maintenance treatment in improving the QOL of opioid-dependent subjects at nine month follow up. These results point towards the need for an expanded nation-wide provision of buprenorphine maintenance treatment as a harm reduction strategy for the opioid dependent population.
authors.affiliation: National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India. anjudh@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Dhawan
authors.forename: A
authors.initials: A
authors.lastname: Chopra
mesh_terms: D000293:Adolescent; D000328:Adult; D000701:Analgesics, Opioid / Q000633:toxicity*; D002047:Buprenorphine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D019966:Substance-Related Disorders / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine